2.52

7.01% -0.19

After Hours: 2.53 0.010 +0.40%

Athira Pharma Inc (ATHA)

Overview News Price History Option Chain Financials Discussions Forecast

Athira Pharma Inc stock is currently priced at $2.52, with a 24-hour trading volume of 180.00K. It has seen a -7.01% decreased in the last 24 hours and a +19.43% rose in the past month. The chart indicates a potential bearish trend, as the stock is below the $2.57 pivot point. If it approaches the $2.38 support level, significant changes may occur.

Previous Close:

$2.71

Open:

$2.7

24h Volume:

180.00K

Market Cap:

$96.58M

Revenue:

Net Income/Loss:

$-117.67M

P/E Ratio:

-0.8905

EPS:

-2.83

Net Cash Flow:

$-101.06M

1W Performance:

+18.87%

1M Performance:

+19.43%

6M Performance:

+49.11%

1Y Performance:

-8.70%

1D Range:

$2.46

$2.70

52W Range:

$1.33

$4.2984

Athira Pharma Inc Stock (ATHA) Company Profile

Name

Athira Pharma Inc

Sector

Healthcare (1209)

Industry

Biotechnology (699)

Phone

206-221-8112

Address

4000 Mason Road, Suite 300, Seattle

Employee

Twitter

Next Earnings Date

2024-05-23

Latest SEC Filings

ATHA's Discussions on Twitter

Athira Pharma Inc Stock (ATHA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-17-22	Upgrade	JMP Securities	Mkt Perform → Mkt Outperform
Jul-07-22	Initiated	Mizuho	Buy
Jun-23-22	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Jun-23-22	Downgrade	Jefferies	Buy → Hold
Jun-23-22	Downgrade	Stifel	Buy → Hold
May-10-22	Initiated	BTIG Research	Buy
Apr-21-22	Initiated	Berenberg	Buy
Dec-15-21	Initiated	Goldman	Neutral
Oct-13-20	Initiated	Goldman	Buy
Oct-13-20	Initiated	JMP Securities	Mkt Outperform
Oct-13-20	Initiated	Jefferies	Buy
Oct-13-20	Initiated	Stifel	Buy

View All

Athira Pharma Inc Stock (ATHA) Latest News

Athira Pharma reaches settlement in shareholder lawsuit By Investing.com - Investing.com Canada

Investing.com Canada

Athira Pharma reaches settlement in shareholder lawsuit By Investing.com - Investing.com Australia

Investing.com Australia

Athira Pharma reaches settlement in shareholder lawsuit By Investing.com - Investing.com

Investing.com

Athira Pharma reaches settlement in shareholder lawsuit - Investing.com ZA - Investing.com South Africa

Investing.com South Africa

Athira Pharma Announces Proposed Settlement of Stockholder Derivative Action - GlobeNewswire

GlobeNewswire

Athira Pharma Announces Proposed Settlement of Stockholder Derivative Action

GlobeNewswire Inc.

Athira Pharma Inc Stock (ATHA) Financials Data

Athira Pharma Inc (ATHA) Net Income 2024

ATHA net income (TTM) was -$117.67 million for the quarter ending December 31, 2023, a -23.04% decrease year-over-year.

Athira Pharma Inc (ATHA) Cash Flow 2024

ATHA recorded a free cash flow (TTM) of -$101.06 million for the quarter ending December 31, 2023, a -37.29% decrease year-over-year.

Athira Pharma Inc (ATHA) Earnings per Share 2024

ATHA earnings per share (TTM) was -$3.09 for the quarter ending December 31, 2023, a -22.13% decline year-over-year.

Athira Pharma Inc Stock (ATHA) Insider Trading

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
Worthington Mark	General Counsel	Jan 05 '24	Sale	2.91	2,412	7,019	34,452
Lenington Rachel	Chief Operating Officer	Jan 05 '24	Sale	2.91	2,412	7,019	13,395
PERCEPTIVE ADVISORS LLC	Director	Dec 29 '23	Buy	2.38	163,954	390,211	5,402,964
PERCEPTIVE ADVISORS LLC	Director	Dec 28 '23	Buy	2.44	409,598	999,419	5,239,010
PERCEPTIVE ADVISORS LLC	Director	Dec 27 '23	Buy	2.28	32,134	73,266	4,829,412
Gengos Andrew	See Below	Jun 07 '23	Buy	3.43	15,000	51,445	80,012
Gengos Andrew	See Below	Jun 05 '23	Buy	3.00	45,000	135,150	65,012
MOEBIUS HANS	Chief Medical Officer	Jun 02 '23	Option Exercise	1.35	7,882	10,641	81,482
Gengos Andrew	See Below	Jun 02 '23	Buy	2.82	20,012	56,422	20,012

Athira Pharma, Inc., a clinical-stage biopharmaceutical company, develops small molecules to restore neuronal health and stop neurodegradation. Its lead product candidate is ATH-1017, a blood brain barrier-penetrating, small hepatocyte growth factor/MET activator that is in various clinical trials for the treatment of Alzheimer's and Parkinson's diseases. The company also develops product candidates, which are in preclinical stage, including ATH-1019 for depression; and ATH-1018 for peripheral neuropathy. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is based in Seattle, Washington.